지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술대회자료
- 저자정보
- 발행연도
- 2021.5
- 수록면
- 315 - 315 (1page)
이용수
초록· 키워드
오류제보하기
Purpose
We conducted this study to evaluate the clinical feasibility of the triplet chemotherapy involving gemcitabine, cisplatin, and nab‐paclitaxel as induction chemotherapy in locally advanced cholangiocarcinoma.
Methods
From October 2019 to October 2020, a total of 15 patients diagnosed with a potentially resectable stage of locally advanced cholangiocarcinoma by a multidisciplinary team and treated with the aforementioned triplet chemotherapy were reviewed.
Results
The median age of study participants was 69 years (range: 42–76 years) and there were nine male patients and six female patients. Three patients were diagnosed with intrahepatic cholangiocarcinoma, eight patients were diagnosed with perihilar cholangiocarcinoma, and four patients were diagnosed with distal cholangiocarcinoma. All patients showed a partial response during an evaluation following induction triplet chemotherapy. Two patients were not able to undergo surgery because of poor performance status, while 13 patients underwent curative surgical resection. 10 patients underwent hepatectomy, and three patients underwent pancreaticoduodenectomy. The median operative time an ... 전체 초록 보기
We conducted this study to evaluate the clinical feasibility of the triplet chemotherapy involving gemcitabine, cisplatin, and nab‐paclitaxel as induction chemotherapy in locally advanced cholangiocarcinoma.
Methods
From October 2019 to October 2020, a total of 15 patients diagnosed with a potentially resectable stage of locally advanced cholangiocarcinoma by a multidisciplinary team and treated with the aforementioned triplet chemotherapy were reviewed.
Results
The median age of study participants was 69 years (range: 42–76 years) and there were nine male patients and six female patients. Three patients were diagnosed with intrahepatic cholangiocarcinoma, eight patients were diagnosed with perihilar cholangiocarcinoma, and four patients were diagnosed with distal cholangiocarcinoma. All patients showed a partial response during an evaluation following induction triplet chemotherapy. Two patients were not able to undergo surgery because of poor performance status, while 13 patients underwent curative surgical resection. 10 patients underwent hepatectomy, and three patients underwent pancreaticoduodenectomy. The median operative time an ... 전체 초록 보기
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Surgical resection after gemcitabine, cisplatin, and nab-paclitaxel chemotherapy for locally advanced cholangiocarcinoma: A retrospective single-center study
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Clinical Feasibility of Curative Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
[Surgical Oncology] Short-term Outcomes of Radical Surgery after nab-Paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Patients with Locally Advanced Perihilar Cholangiocarcinoma
대한외과학회 학술대회 초록집
2022 .11
-
A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
Cancer Research and Treatment
2024 .04
-
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
Cancer Research and Treatment
2017 .01
-
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
Gut and Liver
2022 .09
-
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review
Cancer Research and Treatment
2015 .01
-
Successful radical surgery after neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
대한외과학회 학술대회 초록집
2019 .10
-
Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
Treatment of advanced stage cholangiocarcinoma : Systemic therapy may be the starting step for radical surgery
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .06
-
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
Cancer Research and Treatment
2021 .10
-
Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Obstetrics & Gynecology Science
2019 .01
-
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma
Journal of Gynecologic Oncology
2015 .01
-
Comparison of clinical results of surgical resection for extrahepatic cholangiocarcinomas : hilar cholangiocarcinoma and mid to distal cholangiocarcinoma.
대한외과학회 학술대회 초록집
2017 .11
-
Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Systemic Chemotherapy in Advanced Pancreatic Cancer
Gut and Liver
2016 .01
-
Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
Yonsei Medical Journal
2021 .01
최근 본 자료
댓글(0)
0